TY - JOUR
T1 - Novel controlled-release polylactic-co-glycolic acid (PLGA) nanoparticles for sodium thiosulphate, a hydrogen sulphide donor, retains pro-angiogenic potential of hydrogen sulphide
AU - Marwah, M.K.
AU - Shehzad, S.
AU - Shokr, H.
AU - Sacharczuk, J.
AU - Wang, K.
AU - Ahmad, S.
AU - Sanchez-Aranguren, L.
N1 - Funding Information:
This work was funded by the Joint Research Group Fund 2020 Internal grant awarded to LSA and MM from the College of Health and Life Sciences, Aston University, UK.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/12/31
Y1 - 2022/12/31
N2 - Hydrogen sulphide (H
2S) is an endogenous gaseous signalling molecule observing cardioprotective qualities in various experimental models. However, its therapeutic application is limited due to rapid release in vivo and potential toxicity. Controlled-release nanoparticles (NPs), such as polylactic-co-glycolic acid (PLGA) NPs entrapping H
2S compounds may address these issues. PLGA NPs’ encapsulating sodium thiosulphate (STS), a H
2S donor, were prepared by emulsification and sonication-solvent evaporation in polyvinyl alcohol (PVA). Sonication time was varied between 15 and 45 s and PVA concentration varied between 0.3 and 0.7% w/v. NPs were characterised, cellular uptake, H
2S generation and encapsulated STS angiogenic potential was explored. An increase in sonication time as well as PVA concentration decreased NPs size resulting in an increase in STS release kinetics and cellular uptake over 24 h. Encapsulated STS gave a controlled release of H
2S over 24 h whereas non-encapsulated STS peaked at 2 h. Finally, we observed entrapped STS maintained pro-angiogenic potential. PLGA NPs are a promising controlled-release delivery system with potential to offer sustained H
2S levels. Results of this study demonstrate formulation of STS-loaded PLGA NPs provides a controlled-release of STS and therefore H
2S. NPs are internalised into cells and critically, PLGA NPs are able to maintain the pro-angiogenic potential of H
2S.
AB - Hydrogen sulphide (H
2S) is an endogenous gaseous signalling molecule observing cardioprotective qualities in various experimental models. However, its therapeutic application is limited due to rapid release in vivo and potential toxicity. Controlled-release nanoparticles (NPs), such as polylactic-co-glycolic acid (PLGA) NPs entrapping H
2S compounds may address these issues. PLGA NPs’ encapsulating sodium thiosulphate (STS), a H
2S donor, were prepared by emulsification and sonication-solvent evaporation in polyvinyl alcohol (PVA). Sonication time was varied between 15 and 45 s and PVA concentration varied between 0.3 and 0.7% w/v. NPs were characterised, cellular uptake, H
2S generation and encapsulated STS angiogenic potential was explored. An increase in sonication time as well as PVA concentration decreased NPs size resulting in an increase in STS release kinetics and cellular uptake over 24 h. Encapsulated STS gave a controlled release of H
2S over 24 h whereas non-encapsulated STS peaked at 2 h. Finally, we observed entrapped STS maintained pro-angiogenic potential. PLGA NPs are a promising controlled-release delivery system with potential to offer sustained H
2S levels. Results of this study demonstrate formulation of STS-loaded PLGA NPs provides a controlled-release of STS and therefore H
2S. NPs are internalised into cells and critically, PLGA NPs are able to maintain the pro-angiogenic potential of H
2S.
KW - PLGA
KW - controlled release
KW - hydrogen sulphide donors
KW - nanoparticles
KW - release kinetics
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85128411196&partnerID=MN8TOARS
U2 - 10.1080/17458080.2022.2060963
DO - 10.1080/17458080.2022.2060963
M3 - Article
SN - 1745-8080
VL - 17
SP - 197
EP - 213
JO - JOURNAL OF EXPERIMENTAL NANOSCIENCE
JF - JOURNAL OF EXPERIMENTAL NANOSCIENCE
IS - 1
ER -